PURPOSE: Cigarette smoking is the strongest environmental risk factor for all forms of age-related macular degeneration (AMD). In the present study, the influence of nicotine on the severity of choroidal neovascularization (CNV) in a mouse model of neovascular AMD and its effects on vascular smooth muscle cells derived from mouse choroid were investigated. METHODS: A mouse model for CNV was used to study the effects of nicotine in young and middle-aged mice. Nicotine was administered orally in the drinking water to achieve serum levels consistent with those of chronic smokers. Hexamethonium, a nonspecific nicotinic receptor antagonist, was injected subconjunctivally to counteract the effects of nicotine. A mouse choroidal vascular smooth muscle cell line was exposed to nicotine, vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), or a combination of one of the factors and nicotine. Cell growth was determined by cell counts, and the activity of matrix metalloproteinase (MMP)-2 and -9 was quantified by gel zymography. RESULTS: Nicotine administration resulted in increased size and vascularity of CNV, and older mice developed a greater relative increase than younger mice. This effect was blocked by subconjunctival hexamethonium. Choroidal vascular smooth muscle cells demonstrated a statistically significant increase in growth after exposure to a combination of PDGF and nicotine. Nicotine also reversed VEGF-induced suppression of MMP-2 activity. CONCLUSIONS: Nicotine increases size and severity of experimental CNV in the present mouse model, possibly by potentiating PDGF-mediated upregulation of proliferation of choroidal smooth muscle cells or by other mechanisms. These results suggest that non-neuronal nicotinic receptor activation probably mediates some of the harmful effects of cigarette smoking in wet AMD.
PURPOSE: Cigarette smoking is the strongest environmental risk factor for all forms of age-related macular degeneration (AMD). In the present study, the influence of nicotine on the severity of choroidal neovascularization (CNV) in a mouse model of neovascular AMD and its effects on vascular smooth muscle cells derived from mouse choroid were investigated. METHODS: A mouse model for CNV was used to study the effects of nicotine in young and middle-aged mice. Nicotine was administered orally in the drinking water to achieve serum levels consistent with those of chronic smokers. Hexamethonium, a nonspecific nicotinic receptor antagonist, was injected subconjunctivally to counteract the effects of nicotine. A mouse choroidal vascular smooth muscle cell line was exposed to nicotine, vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), or a combination of one of the factors and nicotine. Cell growth was determined by cell counts, and the activity of matrix metalloproteinase (MMP)-2 and -9 was quantified by gel zymography. RESULTS:Nicotine administration resulted in increased size and vascularity of CNV, and older mice developed a greater relative increase than younger mice. This effect was blocked by subconjunctival hexamethonium. Choroidal vascular smooth muscle cells demonstrated a statistically significant increase in growth after exposure to a combination of PDGF and nicotine. Nicotine also reversed VEGF-induced suppression of MMP-2 activity. CONCLUSIONS:Nicotine increases size and severity of experimental CNV in the present mouse model, possibly by potentiating PDGF-mediated upregulation of proliferation of choroidal smooth muscle cells or by other mechanisms. These results suggest that non-neuronal nicotinic receptor activation probably mediates some of the harmful effects of cigarette smoking in wet AMD.
Authors: Juan Liu; Purushottam Jha; Valeriy V Lyzogubov; Ruslana G Tytarenko; Nalini S Bora; Puran S Bora Journal: J Biol Chem Date: 2011-04-22 Impact factor: 5.157
Authors: Juan A Ayala-Haedo; Paul J Gallins; Patrice L Whitehead; Stephen G Schwartz; Jaclyn L Kovach; Eric A Postel; Anita Agarwal; Gaofeng Wang; Jonathan L Haines; Margaret A Pericak-Vance; William K Scott Journal: Ann Hum Genet Date: 2010-03-31 Impact factor: 1.670
Authors: Chelsea E Myers; Barbara E K Klein; Ronald Gangnon; Theru A Sivakumaran; Sudha K Iyengar; Ronald Klein Journal: Ophthalmology Date: 2014-06-20 Impact factor: 12.079
Authors: G E Nam; B E Hwang; Y-C Lee; J-S Paik; S-W Yang; Y-H Chun; K Han; Y G Park; S H Park Journal: Eye (Lond) Date: 2017-03-10 Impact factor: 3.775
Authors: Nathan G Lambert; Hanan ElShelmani; Malkit K Singh; Fiona C Mansergh; Michael A Wride; Maximilian Padilla; David Keegan; Ruth E Hogg; Balamurali K Ambati Journal: Prog Retin Eye Res Date: 2016-05-06 Impact factor: 21.198
Authors: Jie Jin Wang; Elena Rochtchina; Wayne Smith; Ronald Klein; Barbara E K Klein; Tripti Joshi; Theru A Sivakumaran; Sudha Iyengar; Paul Mitchell Journal: Am J Epidemiol Date: 2008-12-13 Impact factor: 4.897
Authors: Katsuji Kiuchi; Masato Matsuoka; Jenny C Wu; Raquel Lima e Silva; Muralitharan Kengatharan; Mary Verghese; Shinji Ueno; Katsutoshi Yokoi; Naw Htee Khu; John P Cooke; Peter A Campochiaro Journal: Invest Ophthalmol Vis Sci Date: 2008-04 Impact factor: 4.799
Authors: Sankaranarayanan Kaliappan; Purushottam Jha; Valeriy V Lyzogubov; Ruslana G Tytarenko; Nalini S Bora; Puran S Bora Journal: FEBS Lett Date: 2008-09-24 Impact factor: 4.124